NATICK, Mass., May 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), a clinical-stage pharmaceutical company, today announced the upcoming presentation of clinical and preclinical data highlighting its novel first-in-class drug candidates directed against nuclear transport targets for the treatment of cancer at the 19 th Congress of the European Hematology Association (EHA) being held June 12-15, 2014 in Milan, Italy.
"We look forward to presenting interim results from our preclinical studies and clinical trials of Selinexor (KPT-330), our lead drug candidate, at EHA," commented Dr. Sharon Shacham, Karyopharm's Founder, President and CSO. "We are particularly excited to present clinical data for the first time from a combination study of Selinexor, in this case from our Phase 1 clinical trial of Selinexor in advanced hematological malignancies where patients with multiple myeloma have received Selinexor in combination with dexamethasone."
The following abstracts are available through EHA and have been selected for presentation during the Congress:
Oral Presentation:
Title: A Phase I dose escalation study of the oral selective inhibitor of nuclear export selinexor (KPT-330) in patients with relapsed/refractory acute myeloid leukemia (AML). (Abstract S1353)
Date & Time : Sunday, June 15, 11:15-11:30 AM CEST.
Location : Acute Myeloid Leukemia-Clinical 2, Room Red 1+2
Poster Presentations:
Title: The oral selective inhibitor of nuclear export selinexor (KPT-330) activity in double hit diffuse large B-cell lymphomas (DLBCL) in preclinical models & clinical activity in patients with DLBCL. (Abstract P466)
Date & Time : Friday, June 13, 5:45-7:00 PM CEST
Location : Aggressive Non-Hodgkin Lymphoma-Clinical 1
Title: Anti-tumor activity of selinexor (KPT-330), an oral selective inhibitor of nuclear export +/- dexamethasone in multiple myeloma preclinical models & translation in patients with multiple myeloma. (Abstract P953)
Date & Time : Saturday, June 14, 5:45-7:00 PM CEST
Location : Myeloma and other monoclonal gammopathies-Clinical 3
Title: The combination of selinexor (KPT-330), a selective inhibitor of nuclear export, & the FLT3 inhibitor quizatinib shows anti-tumor activity in acute myeloid leukemia (AML) in-vitro and in-vivo . (Abstract P796)
Date & Time : Saturday, June 14, 5:45-7:00 PM CEST
Location : Acute Myeloid Leukemia-Biology 4
Title: XPO1 Inhibition Using Selinexor restores topoisomerase IIa (TOPO IIΑ) localization to the nucleus and sensitize primary refractory and relapsed acute myeloid leukemia (AML) blasts to chemotherapy. (Abstract P801)
Date & Time : Saturday, June 14, 5:45-7:00 PM CEST
Location : Acute Myeloid Leukemia-Biology 4
Title: Evaluation of the novel, orally available selective inhibitor of nuclear export verdinexor (KPT-335) in spontaneous canine cancers: Results of Phase I and Phase II clinical trials. (Abstract P1090)
Date & Time : Saturday, June 14, 5:45-7:00 PM CEST
Location : Aggressive Non-Hodgkin Lymphoma-Clinical 2
About Selinexor
Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor functions by binding with the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. To date, over 300 patients have been treated with Selinexor in Phase 1 and Phase 2 clinical trials in advanced hematologic malignancies and solid tumors. Additional Phase 1 and Phase 2 studies are ongoing or currently planned and three registration-directed clinical trials in hematological indications are expected to begin enrollment during 2014. The latest clinical trial information for Selinexor is available at www.clinicaltrials.gov .
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI ) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts. For more information about Karyopharm, please visit www.karyopharm.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans for Karyopharm's drug candidates, including the timing of initiation of certain trials and of the reporting of data from such trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any of Karyopharm's SINE compounds, including Selinexor (KPT-330), or any other drug candidate that Karyopharm is developing will successfully complete necessary preclinical and clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm's competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission (SEC), and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Paul Brannelly 508-975-4820 Jennifer McNealey 917-392-3400
